Association between the HLA-G molecule and lymph node metastasis in papillary thyroid cancer

Nunes, Larissa Mesquita; Ayres, Flávio Monteiro; Francescantonio, Isadora Carvalho Medeiros; Saddi, Vera Aparecida; Avelino, Melissa Ameloti Gomes; Alencar, Rita de Cássia Gonçalves; Silva, Rosana Correa da; Meneghini, Alexandre J.; Wastowski, Isabela Jubé

doi:10.1016/j.humimm.2012.12.012

Cited by 30 publications

(30 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nunes et al reported HLA-G expression in 44% of PTC cases, for which the HLA-G expression was correlated with a higher frequency of lymph node metastasis. However, the expression of HLA-G in distinct types of benign and malignant thyroid tumors is not well known (3,4). In these studies, HLA-G was highly expressed in thyroid cancer.…”

Section: Discussionmentioning

confidence: 96%

Plasma human leukocyte antigen-G (HLA-G) in patients with thyroid cancer

Akın¹,

Aral²,

Yavuz³

et al. 2017

Turk J Med Sci

View full text Add to dashboard Cite

Background/aim: A number of tumor markers detected in the serum or pathological specimens using immunohistochemical methods are used for early detection of malignancies and postoperative follow-up. Human leukocyte antigen-G (HLA-G) is a nonclassic HLA class I molecule. Recent studies suggested a relationship between HLA-G positivity and the stage or the phenotype of the malignancy. In this study, the relationship between serum HLA-G positivity and thyroid cancer was investigated.Materials and methods: Fifty patients with thyroid cancer and 45 healthy volunteers were included in this study. Serum HLA-G levels were measured using ELISA.Results: HLA-G was positive in only 3 out of 50 patients with thyroid cancer (2 papillary, 1 follicular type). On the other hand, HLA-G was positive in 20 out of 45 healthy subjects (P < 0.001). The prevalence of detectable levels of serum HLA-G was independent of sex and age in the whole study population. No correlation was found between serum HLA-G value and thyroid hormone profile, neither in papillary thyroid cancer nor follicular thyroid cancer patients. Conclusion:In this study, serum HLA-G was significantly less common in patients with thyroid cancer than in healthy controls.

show abstract

Section: Discussionmentioning

confidence: 96%

Plasma human leukocyte antigen-G (HLA-G) in patients with thyroid cancer

Akın¹,

Aral²,

Yavuz³

et al. 2017

Turk J Med Sci

View full text Add to dashboard Cite

show abstract

“…Several lines of evidence indicate that the expression of HLA-G in malignant disorders has been associated with tumour progression, worse prognosis and metastasis, 13 and HLA-G staining has also been previously reported in differentiated thyroid cancer. 15,16 Considering that polymorphic sites along the HLA-G regulatory regions may influence HLA-G expression 14 and considering that scarce information is available about HLA-G polymorphisms and thyroid cancer, in this study we analysed HLA-G 3 0 UTR variability in thyroid disorders exhibiting or not differentiated cancer.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, risk factors associated with worse prognosis, including tumour size and the presence of papillary classic histological subtype in thyroid carcinoma (PTC), were associated with increased HLA‐G expression . Other authors have also observed increased HLA‐G expression in specimens of patients exhibiting PTC and increased plasma soluble HLA‐G (sHLA‐G) levels in patients . To further understand the possible genetic mechanisms involved on the expression of HLA‐G in thyroid disorders, and considering that just the 14‐bp INS/DEL polymorphism has been evaluated in patients with PTC, we studied the complete HLA‐G 3′UTR segment in our previous series of patients.…”

Section: Introductionmentioning

confidence: 99%

HLA‐G 3′ untranslated region polymorphic sites associated with increased HLA‐G production are more frequent in patients exhibiting differentiated thyroid tumours

Figueiredo-Feitosa

Palomino

Alves

et al. 2017

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…High HLA-G expression was present in a quarter of PTC cases and was more than three times more frequent in BRAF V600E compared to BRAF WT tumors. In two studies of thyroid cancer that did not analyze mutational status, HLA-G expression was assoicated with tumor size larger than 1 cm (37) and lymph node metastasis (38) Populations of tumor-infiltrating immune cells were also evaluated in relation to tumor BRAF status. It is now recognized that rather than simply being present, the type, location, functional status, and ratios of immune cells are important to predicting antitumor immunity (17,27).…”

Section: Discussionmentioning

confidence: 99%

BRAF^V600E in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration

Angell

Lechner

Jang

et al. 2014

Thyroid

112

102

View full text Add to dashboard Cite

Background: There remain a small number of patients with papillary thyroid cancer (PTC) who suffer recurrence, metastases, or death. While mutation of the BRAF gene, corresponding to the constitutively active BRAF V600E protein, has been associated with worse clinical outcomes in thyroid cancer, the reasons underlying this observation are presently unknown. Disruption of endogenous host immune surveillance and promotion of tumor immune escape is one mechanism by which BRAF V600E tumors may achieve more aggressive behavior. This study evaluated the relationship between BRAF V600E status and known strategies of tumor-mediated immune suppression. Methods: Tissue sections of PTC tumors from 33 patients were evaluated by immunohistochemistry for tumorexpressed suppressive ligands and enzymes and effector and suppressor populations of tumor-infiltrating immune cells. Presence of BRAF V600E was evaluated by direct DNA sequencing of PTC specimens and the results correlated with tumor-expressed molecules and tumor-infiltrating immune cell populations, as well as patient characteristics and pathologic findings. Results: BRAF V600E tumors more often express high levels of immunosuppressive ligands programmed death ligand 1 (53% vs. 12.5%) and human leukocyte antigen G (41% vs. 12.5%) compared to BRAF wild-type tumors. There was no association between indoleamine 2,3-dioxygenase 1 expression and BRAF V600E status. Furthermore, BRAF V600E tumors demonstrate both lower CD8 + effector to FoxP3 + regulatory T cell, and CD68 + pan-macrophage to CD163 + M2 macrophage ratios, indicating relative increases in suppressive T cell and macrophage components, respectively. Conclusions: Overall, BRAF V600E PTC tumors display a broadly immunosuppressive profile and evidence of disturbed host tumor immune surveillance that may contribute to the poorer outcomes observed in this subset of patients with thyroid cancer.

show abstract

Association between the HLA-G molecule and lymph node metastasis in papillary thyroid cancer

Cited by 30 publications

References 19 publications

Plasma human leukocyte antigen-G (HLA-G) in patients with thyroid cancer

Plasma human leukocyte antigen-G (HLA-G) in patients with thyroid cancer

HLA‐G 3′ untranslated region polymorphic sites associated with increased HLA‐G production are more frequent in patients exhibiting differentiated thyroid tumours

BRAF^V600E in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration

Contact Info

Product

Resources

About

Association between the HLA-G molecule and lymph node metastasis in papillary thyroid cancer

Cited by 30 publications

References 19 publications

Plasma human leukocyte antigen-G (HLA-G) in patients with thyroid cancer

Plasma human leukocyte antigen-G (HLA-G) in patients with thyroid cancer

HLA‐G 3′ untranslated region polymorphic sites associated with increased HLA‐G production are more frequent in patients exhibiting differentiated thyroid tumours

BRAFV600E in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration

Contact Info

Product

Resources

About

BRAF^V600E in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration